# Neoadjuvant and Adjuvant Checkpoint Blockade

> **NCT02519322** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Cutaneous Melanoma
- Mucosal Melanoma
- Ocular Melanoma
- Stage III Acral Lentiginous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIB Uveal Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IIIC Uveal Melanoma AJCC v7
- Stage IV Acral Lentiginous Melanoma AJCC v6 and v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Uveal Melanoma AJCC v7

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Relatlimab
- **PROCEDURE:** Therapeutic Conventional Surgery

## Key facts

- **NCT ID:** NCT02519322
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-02
- **Primary completion:** 2023-01-26
- **Final completion:** 2023-01-26
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02519322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02519322, "Neoadjuvant and Adjuvant Checkpoint Blockade". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02519322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*